Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 10, 2014; 5(5): 931-965
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.931
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.931
Clinical application of DNA ploidy to cervical cancer screening: A review
David Garner, Integrative Oncology Department, British Columbia Cancer Agency, Vancouver, V5Z 1L3, Canada
Author contributions: Garner D solely contributed to this paper.
Correspondence to: David Garner, PhD, Integrative Oncology Department, British Columbia Cancer Agency, 675 w10th Ave., Vancouver, V5Z 1L3, Canada. dmgarner@telus.net
Telephone: +1-604-6758081 Fax: +1-604-6758099
Received: December 30, 2013
Revised: April 21, 2014
Accepted: May 16, 2014
Published online: December 10, 2014
Revised: April 21, 2014
Accepted: May 16, 2014
Published online: December 10, 2014
Core Tip
Core tip: Although application of automated quantitative image cytometry to screen for cervical cancer was first developed in Canada, the United States and Europe, it is most widely used clinically in China where it is applied to about one million tests annually. Over sixty papers reporting the clinical results have been published in Chinese since 2005. As the first review of this topic in any language, in addition to the usual goals of a review, it has the opportunity to increase the awareness of the Chinese clinical experience for those outside of China and to increase awareness of the technology background for English readers in China.